Efficacy of therapy with "Clopidogrel" ("Plavix")

A genetic study that allows determining the efficacy of "Clopidogrel" use based on the activity of the CYP2C19 enzyme.

When is it prescribed?

• Personalized selection of antiplatelet agents for patients
• Determination of the prognosis of drug efficacy for the prevention of atherothrombotic complications in patients who have had myocardial infarction, ischemic stroke, or with diagnosed peripheral artery occlusive disease
• Determination of the prognosis of drug efficacy in patients with acute coronary syndrome:
- without ST-segment elevation (unstable angina or non-Q wave myocardial infarction), including patients who underwent stenting during percutaneous coronary intervention;
- with ST-segment elevation (acute myocardial infarction) during medical treatment and the possibility of thrombolysis.

Examination results are provided with an interpretation by a geneticist.

Within 6 days. The specified time does not include the day of biomaterial collection